An overview of harms associated with β-lactam antimicrobials: Where do the carbapenems fit in?

Critical Care

Volumn 12, Issue SUPPL. 4, 2008, Pages

  Owens Jr , Robert C ^a  

^a MAINE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CEPHALOSPORIN; CEPHAMYCIN; CIPROFLOXACIN; CYTOCHROME P450 INHIBITOR; DORIPENEM; ERTAPENEM; ERYTHROMYCIN; GATIFLOXACIN; IMIDAZOLE; IMIPENEM; KETOLIDE; LATAMOXEF; MACROLIDE; MEROPENEM; MONOBACTAM; OXACILLIN; PENICILLIN G; PIPERACILLIN; PYRROLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TRIAZOLE; UNINDEXED DRUG;

ANAPHYLAXIS; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CONTINUOUS INFUSION; DISEASE CLASSIFICATION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BINDING; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INFORMATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEART ARREST; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMMUNE RESPONSE; INTENSIVE CARE; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; PATIENT SAFETY; PENICILLIN ALLERGY; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; REVIEW; RISK FACTOR; SEIZURE; SKIN TEST; STOMACH ACID SECRETION; TORSADE DES POINTES; TREATMENT DURATION; URTICARIA; VOMITING; ANTIBIOTIC RESISTANCE; CENTRAL NERVOUS SYSTEM DISEASE; CHEMICALLY INDUCED DISORDER; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG EFFECT; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HEART DISEASE; MULTIDRUG RESISTANCE;

CARBAPENEMS; CENTRAL NERVOUS SYSTEM DISEASES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE; GLUCOSE METABOLISM DISORDERS; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HEART DISEASES; HUMANS;

EID: 45949105377     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc6819     Document Type: Review

References (79)

1. Food and Drug Administration FDA announces label and indication changes for the antibiotic Ketek http://www.fda.gov/bbs/topics/NEWS/2007/ NEW01561.html
2. Food and Drug Administration Centers for Drug Evaluation and Research Clinical therapeutics and recognition of drug induced disease http://www.fda.gov/medwatch/articles/dig/ceart.pdf
3. Robinson JL Hameed T Carr S Practical aspects of choosing an antibiotic for patients with a reported allergy to an antibiotic Clin Infect Dis 2002, 35:26-31. 10.1086/340740 12060871
4. Weiss ME Adkinson NF β-Lactam allergy Principles and Practice of Infectious Diseases Philadelphia, PA: Churchill Livingston Mandell GL, Bennett JE, Dolin R 2000, 299-305.
5. US FDA website http://www.fda.gov
6. Maroko R Cooper A Dukart G Dartios H Results of phase 3 study comparing a tigecycline regimen with an imipenem/cilastatin regimen in treatment of patients with hospital acquired pneumonia [poster L-730] Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL; 17 to 21 September 2007 Washington, DC: American Society of Microbiology 2007
7. Lasser KE Allen PD Woolhandler SJ Himmelstein DU Wolfe SM Bor DH Timing of new black box warnings and withdrawals for prescription medications JAMA 2002, 287:2215-2220. 10.1001/jama.287.17.2215 11980521
8. Leape LL Brennan TA Laird N Lawthers AG Localio AR Barnes BA Hebert L Newhouse JP Weiler PC Hiatt H The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II N Engl J Med 1991, 324:377-384. 1824793
9. Fermini B Fossa AA The impact of drug-induced QT interval prolongation on drug discovery and development Nat Rev Drug Discov 2003, 2:439-447. 10.1038/nrd1108 12776219
10. Owens RC Jr QT prolongation with antimicrobial agents: Understanding the significance Drugs 2004, 64:1091-1124. 10.2165/00003495-200464100-00005 15139788
11. Owens RC Jr Nolin TD Antimicrobial-associated QT interval prolongation: pointes of interest Clin Infect Dis 2006, 43:1603-1611. 10.1086/508873 17109296
12. Bertino JS Jr Owens RC Jr Carnes TD Iannini PB Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors Clin Infect Dis 2002, 34:861-863. 10.1086/339075 11830802
13. Owens RC Jr Ambrose PG Antimicrobial safety: Focus on fluoroquinolones Clin Infect Dis 2005, 41(suppl 2):S144-S157. 10.1086/428055 15942881
14. Morganroth J Ilson BE Shaddinger BC Dabiri GA Patel BR Boyle DA Sethuraman VS Montague TH Evaluation of vardenafil and sildenafil on cardiac repolarization Am J Cardiol 2004, 93:1378-1383. A6. 10.1016/ j.amjcard.2004.02.034 15165918
15. Owens RC Jr Fluoroquinolone-associated dysglycemias: A tale of two toxicities Pharmacotherapy 2005, 25:1291-1295. 10.1592/ phco.2005.25.10.1291 16185171
16. Maeda N Tamagawa T Niki I Miura H Ozawa K Watanabe G Nonogaki K Uemura K Iguchi A Increase in insulin release from rat pancreatic islets by quinolone antibiotics Br J Pharmacol 1996, 117:372-376. 1909264 8789393
17. Owens RC Clostridium difficile-associated disease: An emerging threat to patient safety: Insights from the Society of Infectious Diseases Pharmacists Pharmacotherapy 2006, 26:299-311. 10.1592/phco.26.3.299 16503710
18. Gerding DN Muto CA Owens RC Jr Measures to control and prevent Clostridium difficile infection Clin Infect Dis 2008, 46:S43-S49. 10.1086/521861 18177221
19. Owens RC Clostridium difficile-associated disease: Changing epidemiology and implications for management Drugs 2007, 67:487-502. 10.2165/ 00003495-200767040-00001 17352510
20. Owens RC Jr Donskey CJ Gaynes RP Loo VG Muto CA Antimicrobial-associated risk factors for Clostridium difficile infection Clin Infect Dis 2008, 46:S19-S31. 10.1086/521859 18177218
21. Gerding DN Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: This is an antimicrobial resistance problem Clin Infect Dis 2004, 38:646-648. 10.1086/382084 14986247
22. Hecht DW Galang MA Sambol SP Osmolski JR Johnson S Gerding DN In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004 Antimicrob Agents Chemother 2007, 51:2716-2719. 1932509 17517836 10.1128/ AAC.01623-06
23. Bignardi GE Risk factors for Clostridium difficile infection J Hosp Infect 1998, 40:1-15. 10.1016/S0195-6701(98)90019-6 9777516
24. Owens RC Jr Ambrose PG Antimicrobial stewardship and the role of pharmacokinetics-pharmacodynamics in the modern antibiotic era Diagn Microbiol Infect Dis 2007, 57(suppl):77S-83S. 10.1016/ j.diagmicrobio.2006.12.012
25. Itani KM Wilson SE Awad SS Jensen EH Finn TS Abramson MA Ertapenem versus cefotetan prophylaxis in elective colorectal surgery N Engl J Med 2006, 355:2640-2651. 10.1056/NEJMoa054408 17182989
26. Bodey G Abi-Said D Rolston K Raad I Whimbey E Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients Eur J Clin Microbiol Infect Dis 1996, 15:625-634. 10.1007/BF01691147 8894569
27. Pépin J Saheb N Coulombe MA Alary ME Corriveau MP Authier S Leblanc M Rivard G Bettez M Primeau V Nguyen M Jacob CE Lanthier L Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: A cohort study during an epidemic in Quebec Clin Infect Dis 2005, 41:1254-1260. 10.1086/496986 16206099
28. Owens RC Jr Nolin TD QT reply to Chinello and Petrosillo [letter] Clin Infect Dis 2007, 44:1389-1391. 10.1086/516613
29. Ray WA Murray KT Meredith S Narasimhulu SS Hall K Stein CM Oral erythromycin and the risk of sudden death from cardiac causes N Engl J Med 2004, 351:1089-1096. 10.1056/NEJMoa040582 15356306
30. Segarra-Newnham M Tagoff SS Probable vancomycin-induced neutropenia Ann Pharmacother 2004, 38:1855-1859. 10.1345/aph.1E187 15466904
31. Smilack JD Trimethoprim-sulfamethoxazole Mayo Clin Proc 1999, 74:730-734. 10405706
32. Chambers HF Penicillins Principles and Practice of Infectious Diseases Philadelphia, PA: Churchill Livingston Mandell GL, Bennett JE, Dolin R 2000, 299-305.
33. Karchmer AW Cephalosporins Principles and Practice of Infectious Diseases Philadelphia, PA: Churchill Livingston Mandell GL, Bennett JE, Dolin R 2000, 299-305.
34. Wilson DL Owens RC Jr Zuckerman JB Successful meropenem desensitization in a patient with cystic fibrosis Ann Pharmacother 2003, 37:1424-1428. 10.1345/aph.1D022 14519038
35. Prescott WA Jr Kusmierski KA Clinical importance of carbapenem hypersensitivity in patients with self-reported and documented penicillin allergy Pharmacotherapy 2007, 27:137-142. 10.1592/ phco.27.1.137 17192167
36. Forrest DM Schellenberg RR Thien VV King S Anis AH Dodek PM Introduction of a practice guideline for penicillin skin testing improves the appropriateness of antibiotic therapy Clin Infect Dis 2001, 32:1685-1690. 10.1086/320752 11360207
37. McConnell SA Penzak SR Warmack TS Anaissie EJ Gubbins PO Incidence of imipenem hypersensitivity reactions in febrile neutropenic bone marrow transplant patients with a history of penicillin allergy Clin Infect Dis 2000, 31:1512-1514. 10.1086/317507 11096026
38. Prescott WA Jr DePestel DD Ellis JJ Regal RE Incidence of carbapenem-associated allergic-type reactions among patients with versus patients without a reported penicillin allergy Clin Infect Dis 2004, 38:1102-1107. 10.1086/382880 15095214
39. Sodhi M Axtell SS Callahan J Shekar R Is it safe to use carbapenems in patients with a history of allergy to penicillin? J Antimicrob Chemother 2004, 54:1155-1157. 10.1093/jac/dkh454 15486083
40. Chen HJ Bloch KJ Maclean JA Acute eosinophilic hepatitis from trovafloxacin N Engl J Med 2000, 342:359-360. 10.1056/ NEJM200002033420517 10660405
41. Maraqa NF Gomez MM Rathore MH Alvarez AM Higher occurrence of hepatotoxicity and rash in patients treated with oxacillin, compared with those treated with nafcillin and other commonly used antimicrobials Clin Infect Dis 2002, 34:50-54. 10.1086/338047 11731945
42. Nicholson SC Webb CD Moellering RC Jr Antimicrobial-associated acute hepatitis Pharmacotherapy 2002, 22:794-796. 10.1592/phco.22.9.794.34066 12066973
43. Vial T Biour M Descotes J Trepo C Antibiotic-associated hepatitis: update from 1990 Ann Pharmacother 1997, 31:204-220. 9034423
44. Owens RC Jr Ambrose PG Clinical use of the fluoroquinolones Med Clin North Am 2000, 84:1447-1469. 10.1016/S0025-7125(05)70297-2 11155852
45. Rao N Ziran BH Wagener MM Santa ER Yu VL Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections Clin Infect Dis 2004, 38:1058-1064. 10.1086/382356 15095207
46. Charak BS Louie R Malloy B Twomey P Mazumder A The effect of amphotericin B, aztreonam, imipenem and cephalosporins on the bone marrow progenitor cell activity J Antimicrob Chemother 1991, 27:95-104. 10.1093/jac/27.1.95 2050599
47. Calandra G Lydick E Carrigan J Weiss L Guess H Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin Am J Med 1988, 84:911-918. 10.1016/ 0002-9343(88)90071-X 3284342
48. Sullivan EA Geoffroy P Weisman R Hoffman R Frieden TR Isoniazid poisonings in New York City J Emerg Med 1998, 16:57-59. 10.1016/ S0736-4679(97)00242-4 9472761
49. Yang J Teng Q Federici T Najm I Chabardes S Moffitt M Alexopoulos A Riley Boulis NM Viral clostridial light chain gene-based control of penicillin-induced neocortical seizures Mol Ther 2007, 15:542-551. 10.1038/sj.mt.6300069 17213837
50. Eng RH Munsif AN Yangco BG Smith SM Chmel H Seizure propensity with imipenem Arch Intern Med 1989, 149:1881-1883. 10.1001/ archinte.149.8.1881 2669668
51. Raad II bi-Said D Rolston KV Karl CL Bodey GP How should imipenem-cilastatin be used in the treatment of fever and infection in neutropenic cancer patients? Cancer 1998, 82:2449-2458. 10.1002/ (SICI)1097-0142(19980615)82:12<2449::AID-CNCR20>3.0.CO;2-O 9635539
52. Zajac BA Fisher MA Gibson GA MacGregor RR Safety and efficacy of high-dose treatment with imipenem-cilastatin in seriously ill patients Antimicrob Agents Chemother 1985, 27:745-748. 180145 3860187
53. Wong VK Wright HT Jr Ross LA Mason WH Inderlied CB Kim KS Imipenem/ cilastatin treatment of bacterial meningitis in children Pediatr Infect Dis J 1991, 10:122-125. 2062603
54. Merck and Co Primaxin® IV (Imipenem and Cilastatin for Injection) Package Insert Whitehouse Station, NJ: Merck and Co 2005
55. AstraZeneca Merrem® IV (Meropenem for Injection) Package Insert Wilmington, DE: AstraZeneca 2005
56. Merck and Co Invanz® (Ertapenem for Injection) Package Insert Whitehouse Station, NJ: Merck and Co 2005
57. Horiuchi M Kimura M Tokumura M Hasebe N Arai T Abe K Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics Toxicology 2006, 222:114-124. 10.1016/j.tox.2006.02.004 16549226
58. Chow KM Szeto CC Hui ACF Wong TYH Li TL Retrospective review of neurotoxicity induced by cefepime and ceftazidime Pharmacotherapy 2003, 23:369-373. 10.1592/phco.23.3.369.32100 12627936
59. Sonck J Laureys G Verbeelen D The neurotoxicity and safety of treatment with cefepime in patients with renal failure Nephrol Dial Transplant 2008, 23:966-970. 10.1093/ndt/gfm713 18175786
60. Owens RC Jr Ambrose PG Antimicrobial safety: Focus on fluoroquinolones Clin Infect Dis 2005, 40:S456-69.
61. Ambrose PG Owens RC Jr Garvey MJ Jones RN Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime J Antimicrob Chemother 2002, 49:445-453. 10.1093/jac/49.3.445 11864944
62. Livermore DM Woodford N The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter Trends Microbiol 2006, 14:413-420. 10.1016/ j.tim.2006.07.008 16876996
63. Fish DN Piscitelli SC Danziger LH Development of resistance during antimicrobial therapy: A review of antibiotic classes and patient characteristics in 173 studies Pharmacotherapy 1995, 15:279-291. 7667163
64. Bonfiglio G Russo G Nicoletti G Recent developments in carbapenems Expert Opin Investig Drugs 2002, 11:529-544. 10.1517/13543784.11.4.529 11922861
65. Chastre J Wolff M Fagon JY Chevret S Thomas F Wermert D Clementi E Gonzalez J Jusserand D Asfar P Perrin D Fieux F Aubas S PneumA Trial Group Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial JAMA 2003, 290:2588-2598. 10.1001/jama.290.19.2588 14625336
66. Gilbert DN Moellering RC Eliopoulos GM Sande MA The Sanford Guide to Antimicrobial Therapy 2006 (Guide to Antimicrobial Therapy) Sperryville, VA: Antimicrobial Therapy Inc 36, 2006.
67. Calandra GB Ricci FM Wang C Brown KR The efficacy results and safety profile of imipenem/cilastatin from the clinical research trials J Clin Pharm 1988, 28:120-127.
68. Carmeli Y Troillet N Eliopoulos GM Samore MH Emergence of antibiotic-resistant Pseudomonas aeruginosa: Comparison of risks associated with different antipseudomonal agents Antimicrob Agents Chemother 1999, 43:1379-1382. 89282 10348756
69. Georges B Conil JM Dubouix A Archambaud M Bonnet E Saivin S Lauwers-Cances V Cristini C Cougot P Decun JF Mathe O Chabonon G Marty N Sequin T Houin G Risk of emergence of Pseudomonas aeruginosa resistance to beta-lactam antibiotics in intensive care units Crit Care Med 2006, 34:1636-1641. 10.1097/01.CCM.0000215517.51187.CA 16557152
70. Harbarth S Harris AD Carmeli Y Samore MH Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram-negative bacilli Clin Infect Dis 2001. 33:1462-1468. 10.1086/322677 11588690
71. Harris AD Smith D Johnson JA Bradham DD Roghmann MC Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients Clin Infect Dis 2002, 34:340-345. 10.1086/338237 11774081
72. Winston DJ McGrattan MA Busuttil RW Imipenem therapy of Pseudomonas aeruginosa and other serious bacterial infections Antimicrob Agents Chemother 1984, 26:673-677. 179992 6595961
73. Livermore DM Of Pseudomonas, porins, pumps and carbapenems J Antimicrob Chemother 2001, 47:247-250. 10.1093/jac/47.3.247 11222556
74. Blumer JL Saiman L Konstan MW Melnick D The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis Chest 2005, 128:2336-2346. 10.1378/chest.128.4.2336 16236892
75. Lodise TP Lomaestro BM Drusano GL Practical application of pharmacodynamic principles to optimize therapy and treat resistant organisms: A focus on beta-lactam antibiotics Antimicrobial Resistance: Problem Pathogens and Clinical Countermeasures Informa Healthcare Owens RC Jr, Lautenbach E 2008 317 335
76. Lomaestro BM Drusano GL Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation Antimicrob Agents Chemother 2005, 49:461-463. 538854 15616337 10.1128/ AAC.49.1.461-463.2005
77. Wang C Calandra GB Aziz MA Brown KR Efficacy and safety of imipenem/ cilastatin: A review of worldwide clinical experience Rev Infect Dis 1985, 7(suppl 3):S528-S536. 3901217
78. Viaene E Chanteux H Servais H Mingeot-Leclercq MP Tulkens PM Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units) Antimicrob Agents Chemother 2002, 46:2327-2332. 127357 12121900 10.1128/AAC.46.8.2327-2332.2002
79. Eagle H Fleischman R Levy M Continuous versus discontinuous therapy with penicillin N Engl J Med 1953, 238:481-486.